Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditioning Regimens

Modulations of dose intensity of doxorubicin and cyclophosphamide in association with G-CSF and peripheral blood stem cells in adjuvant chemotherapy for breast cancer: comparative evaluation of completion and safety of three intensive regimens

Abstract

The aim of this study was to evaluate and to compare in terms of toxicity the modulations of dose intensity of cyclophosphamide and doxorubicin in adjuvant chemotherapy for high-risk breast cancer. Four cycles of sequential high-dose chemotherapy with doxorubicin and cyclophosphamide (AC), supported with G-CSF and peripheral blood stem cells (PBSC) were administered to 81 women. Three successive cohorts were studied: doxorubicin (75 mg/m2) + cyclophosphamide (3000 mg/m2) every 21 days (group 1), doxorubicin (75 mg/m2) + cyclophosphamide (3000 mg/m2) every 15 days (group 2), and doxorubicin (75 mg/m2) + cyclophosphamide (6000 mg/m2) every 21 days (group 3). Seventy-five patients received four cycles of treatment with a total of 310 cycles administered. The received dose intensity of doxorubicin was higher in group 2 and that of cyclophosphamide was lower in group 1 than in the other two groups. Hematological and extra-hematological toxicities, as well as the number and duration of hospitalizations for toxicity, were significantly higher in group 3. We conclude that the group 3 regimen is associated with toxicities comparable to autologous transplantation. Increasing dose intensity of doxorubicin and cyclophosphamide is feasible in an outpatient setting and safe in groups 1 and 2 with the support of hematopoietic factor and PBSC.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Similar content being viewed by others

References

  1. Fisher B, Brown AM, Dimitrov NV et al. Two months of doxorubicin–cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate and fluorouracil in positive-node breast cancer patients with tamoxifen-non responsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15 J Clin Oncol 1990 8: 1483 1496

    Article  CAS  Google Scholar 

  2. Von Hoff DD, Clark GM, Weiss GR et al. Use of in vitro dose response effects to select antineoplastics for high-dose or regional administration regimens J Clin Oncol 1986 4: 1827 1834

    Article  CAS  Google Scholar 

  3. Piccart MJ, Biganzoli L, Di Leo A . The impact of chemotherapy dose density and dose intensity on breast cancer outcome: what have we learned? Eur J Cancer 2000 36: (Suppl. 1) S4 10

    Article  CAS  Google Scholar 

  4. Norton L . Evolving concepts in the systemic drug therapy of breast cancer Semin Oncol 1997 24: S10-3 S10-10

    Google Scholar 

  5. Ardizzoni A, Venturini M, Sertoli MR et al. Granulocyte–macrophage colony-stimulating factor (GM-CSF) allows acceleration and dose intensity increase of CEF chemotherapy: a randomised study in patients with advanced breast cancer Br J Cancer 1994 69: 385 391

    Article  CAS  Google Scholar 

  6. Del Mastro L, Garrone O, Sertoli MR et al. A pilot study of accelerated cyclophosphamide, epirubicin and 5-fluorouracil plus granulocyte colony stimulating factor as adjuvant therapy in early breast cancer Eur J Cancer 1994 30A: 606 610

    Article  CAS  Google Scholar 

  7. Scinto AF, Ferraresi V, Campiioni N et al. Accelerated chemotherapy with high-dose epirubicin and cyclophosphamide plus r-met-HUG-CSF in locally advanced and metastatic breast cancer Ann Oncol 1995 6: 665 671

    Article  CAS  Google Scholar 

  8. Budd GT, Atiba J, Silver RT et al. Phase I/II trial of human recombinant granulocyte-colony-stimulating factor (filgrastim) and escalating doses of cyclophosphamide, mitoxantrone, and 5-FU in the treatment of advanced breast cancer J Cancer Res Clin Oncol 1999 125: 500 504

    Article  CAS  Google Scholar 

  9. Hohaus S, Martin S, Schneeweiss A et al. Adjuvant high-dose therapy with peripheral blood stem cell support for patients with high-risk breast cancer Cancer Chemother Pharmacol 1999 44: S13 17

    Article  CAS  Google Scholar 

  10. Viens P, Gravis G, Genre D et al. High-dose sequential chemotherapy with stem cell support for non-metastatic breast cancer Bone Marrow Transplant 1997 20: 199 203

    Article  CAS  Google Scholar 

  11. Hryniuk WM . The importance of dose intensity in the outcome of chemotherapy Important Adv Oncol 1988 121 141

  12. Hryniuk W, Levine MN . Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer J Clin Oncol 1986 4: 1162 1170

    Article  CAS  Google Scholar 

  13. Hryniuk WM . Average relative dose intensity and the impact on design of clinical trials Semin Oncol 1987 14: 65 74

    CAS  PubMed  Google Scholar 

  14. Siegel S, Castellan N . Nonparametric statistics for the Behavioural Sciences McGraw Hill: New York 1988

    Google Scholar 

  15. Stoppa AM, Bouabdallah R, Chabannon C et al. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma J Clin Oncol 1997 15: 1722 1729

    Article  CAS  Google Scholar 

  16. Bouabdallah R, Stoppa AM, Rossi JF et al. Intensive sequential chemotherapy (ISC 95) with growth factors and blood stem cell support in high-intermediate and high-risk (IPI 2 and IPI 3) aggressive non-Hodgkin's lymphoma: an oligocentric report of 42 patients Leukemia 1999 13: 950 956

    Article  CAS  Google Scholar 

  17. Hartmann O, Le Corroller AG, Blaise D et al. Peripheral blood stem cell and bone marrow transplantation for solid tumors and lymphomas: hematologic recovery and costs. A randomized, controlled trial Ann Intern Med 1997 126: 600 607

    Article  CAS  Google Scholar 

  18. Le Coroller AG, Faucher C, Auperin A et al. Autologous peripheral blood progenitor-cell transplantation versus autologous bone marrow transplantation for adults and children with non-leukaemic malignant disease. A randomised economic study Pharmacoeconomics 1997 11: 454 463

    Article  Google Scholar 

  19. Oddou S, Vey N, Viens P et al. Second neoplasms following high-dose chemotherapy and autologous stem cell transplantation for malignant lymphomas: a report of six cases in a cohort of 171 patients from a single institution Leuk Lymphoma 1998 31: 187 194

    Article  CAS  Google Scholar 

  20. Curtis RE, Rowlings PA, Deeg HJ et al. Solid cancers after bone marrow transplantation New Engl J Med 1997 336: 897 904

    Article  CAS  Google Scholar 

  21. Chaplain G, Milan C, Sgro C et al. Increased risk of acute leukemia after adjuvant chemotherapy for breast cancer: a population-based study J Clin Oncol 2000 18: 2836 2842

    Article  CAS  Google Scholar 

  22. Linassier C, Barin C, Calais G et al. Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluorouracil and radiation therapy Ann Oncol 2000 11: 1289 1294

    Article  CAS  Google Scholar 

  23. Diamandidou E, Buzdar AU, Smith TL et al. Treatment-related leukemia in breast cancer patients treated with fluorouracil-doxorubicin-cyclophosphamide combination adjuvant chemotherapy: the University of Texas MD Anderson Cancer Center experience J Clin Oncol 1996 14: 2722 2730

    Article  CAS  Google Scholar 

  24. Gianni A, Bonadonna G . Five year results of randomized clinical trial comparing standard versus high-dose myeloblative chemotherapy in the adjuvant treatment of breast cancer with >3 positive nodes (LN+) In: ASCO's 37th Annual Meeting; 2001 May 12–15; San Francisco, CA Am Soc Clin Oncol 2001 21A: (Abstr. 634)

  25. Roche H, Pouillart P, Meyer N et al. Adjuvant high dose chemotherapy (HDC) improves early outcome for high risk (N>7) breast cancer patients: the Pegase 01 trial In: ASCO's 37th Annual Meeting; 2001; San Francisco, CA Am Soc Clin Oncol 2001 18A: (Abstr. 316)

Download references

Acknowledgements

This work received special grants from the French Administration of Health (PHRC) and Amgen France.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Genre, D., Viens, P., Bertucci, F. et al. Modulations of dose intensity of doxorubicin and cyclophosphamide in association with G-CSF and peripheral blood stem cells in adjuvant chemotherapy for breast cancer: comparative evaluation of completion and safety of three intensive regimens. Bone Marrow Transplant 29, 881–886 (2002). https://doi.org/10.1038/sj.bmt.1703556

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.bmt.1703556

Keywords

Search

Quick links